Drug Trial Radar · NCT06696768
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Jun 23, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Nov 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies the side effects and best dose of CA-4948 when given together with fluorouracil, leucovorin, oxaliplatin (FOLFOX) plus bevacizumab in treating patients with colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). CA-4948 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The chemotherapy drugs used in FOLFOX, fluorouracil and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Leucovorin is used with fluorouracil to treat colorectal cancer. Bevacizumab is in a class of medications called anti-angiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to the tumor. This may slow the growth and spread of the tumor. Giving CA-4948 with FOLFOX plus bevacizumab may be safe, tolerable and/or effective in treating patients with metastatic colorectal cancer.
Conditions
- Metastatic Colorectal Adenocarcinoma
- Stage III Colorectal Cancer AJCC v8
- Stage IV Colorectal Cancer AJCC v8
- Unresectable Colorectal Adenocarcinoma
Interventions
BevacizumabBiological
Given IV
Biopsy ProcedureProcedure
Undergo tumor biopsy
Biospecimen CollectionProcedure
Undergo blood sample collection
Computed TomographyProcedure
Undergo CT or PET/CT
EmavusertibBiological
Given PO
FluorouracilDrug
Given IV
Leucovorin CalciumDrug
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
OxaliplatinDrug
Given IV
Positron Emission TomographyProcedure
Undergo PET/CT
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicities (DLT)Time frame: Up to 2 cycles (Cycle length = 14 days)
- Incidence of treatment-emergent adverse eventsTime frame: Up to 2 cycles (Cycle length = 14 days)
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
UF Health Cancer Institute - Gainesville
Gainesville, Florida · Recruiting
Memorial Hospital East
Shiloh, Illinois · Recruiting
University of Kansas Clinical Research Center
Fairway, Kansas · Recruiting
University of Kansas Cancer Center
Kansas City, Kansas · Recruiting
University of Kansas Hospital-Indian Creek Campus
Overland Park, Kansas · Recruiting
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas · Recruiting
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri · Recruiting
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Siteman Cancer Center-South County
St Louis, Missouri · Recruiting
Siteman Cancer Center at Christian Hospital
St Louis, Missouri · Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma · Recruiting
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.